MD_PERELIGYN — Holistic & Integrative Medicine — Dr. Vladimir Pereligyn
Ways to Work Together
Four formats — from a lab review to a full month of supervision. Card payment (EUR), works from most countries.
Lab Review
€100
Review of your lab results with prescriptions based on them.
- Written summary of your lab results
- Prescription list
- Recommendations for further testing
Consultation + Follow-up Review
€250
Full review → prescriptions → follow-up review → recommendations.
- Full review of your condition and labs
- Prescription list
- Follow-up review of control labs
- Final recommendations
2-Week Support
€500
Two weeks of work with the team + a nutritionist on board.
- Everything in Consultation + Follow-up Review
- Two weeks of active supervision
- Nutritionist consultation and guidance
- Plan adjustments along the way
VIP — Full Month
€1,000
30 days of full supervision: doctor, nutritionist, and specialist consultations arranged for you.
- Intake form and electronic medical record
- Clinical assessment and lab test list
- Health map and root-cause identification
- Personalized treatment plan and prescription list
VIP — Full Month — €1,000
Online payment will be available soon. Message us on WhatsApp to book your consultation.
Ask a Question
Health Shop
Detailed Treatment Programs
Personalized recovery protocols for complex medical conditions
Diabetes Treatment
Comprehensive treatment for type 1 and type 2 diabetes
Burnout Treatment
Comprehensive recovery from emotional and physical exhaustion
Anti-aging Program
Slowing aging processes and optimizing longevity
Medical Tourism
News and Articles
Current materials on health, holistic medicine and my programs
Modafinil: mechanism, indications and comparison with other wake-promoting agents
A review of modafinil based on labels from the FDA, EMA and other regulators and on research: what is known about the mechanism (officially it is unknown), duration of action, indications in the US, EU, UK, Switzerland, Japan, Canada, Australia and South Korea, efficacy in RCTs, off-label use, comparison with armodafinil, caffeine, stimulants, solriamfetol, pitolisant and oxybate, interaction with hormonal contraception, pregnancy and safety.
October 2, 2026
5 foods that lower bad cholesterol: how much to eat and how far LDL falls
Five foods that lower "bad" cholesterol in meta-analyses — LDL cholesterol (low-density lipoprotein): daily amounts, figures in mmol/L and mg/dL, and honest caveats. Why the places are provisional, what is known about heart attacks, who foods with added sterols may not suit, and why food does not replace a prescribed statin.
October 1, 2026
Iron and thyroid pills: why 4 hours, and when to check ferritin
One person can take a thyroid pill and iron if the two are separated in time — though even the gap does not help everyone. We look at where the 4 hours came from and why some leaflets say 2, what a small study of taking them together showed, why iron is not stopped when there is a deficiency, and when it is worth checking ferritin.
September 24, 2026
Haemochromatosis is not missed in the lab report — most often, the test is simply never ordered
Hereditary haemochromatosis is found late not because it is hard to recognise, but because the right test is most often never ordered. We look at data from large biobanks, at which two of the four iron markers actually detect the disease, and at who should have them checked first.
September 18, 2026
Ten healthy diets compared against biological age. The gap between them is smaller than it looks
German researchers took ten recognised healthy-eating scores — Mediterranean, DASH, MIND, Nordic and others — and matched them against epigenetic clocks in 6470 people. The interesting part is not which diet won, but two things the write-ups tend to drop.
September 17, 2026
Transferrin saturation: why a single number cannot be trusted
A single high transferrin saturation is not a diagnosis, and not even grounds for genetic testing. In five short pages: what the number is made of, why it moves, where the real thresholds are, and what to do next.
September 17, 2026
Berberine for SIBO: first in the ranking, with nothing yet to compare it against
Berberine came first in a network meta-analysis of SIBO treatments — and that is true. But a ranking is not «it beat rifaximin»: no head-to-head comparison has been published, and one is running right now. What is actually shown, what the dose is in milligrams, and why safety matters more here than efficacy.
September 16, 2026SIBO: what the breath test shows, and why the order of steps matters more than the remedy
SIBO is both under-recognised and over-diagnosed, and the same breath test is responsible for each. What it actually measures and what it cannot do, why methane is not bacteria at all, where overgrowth comes from, and what a study found in thirty patients with brain fog — every one of whom was taking probiotics.
September 15, 2026Four systems worth watching
All four of the conditions people come with most often share one trait: they begin long before any complaint and give nothing away for years. So prevention is not a list of supplements. It is the habit of looking.
September 13, 2026Orforglipron: the first pill instead of an injection — and what it actually does
Every GLP-1 drug so far has been an injection — not by design but by chemistry: they are proteins, and the stomach digests them. Orforglipron is built differently and therefore works as a tablet. What the trial in 3127 people showed, why the pill is weaker than the injection and what it is for anyway, and what the label says in small print.
September 13, 2026The Strongest Opioid Painkillers: What Potency Actually Means
A list of opioids by potency reads like a ranking: sufentanil, fentanyl, buprenorphine, then the rest. But the study those numbers come from did not measure the quality of relief — it measured how much of the drug patients gave themselves before the pain let go. And the European guideline published this year argues directly against the habit of sorting opioids into weak and strong. Here is what sits behind the figures, and why the strongest drug in the table does not exist outside a hospital.
September 11, 2026Suzetrigine (Journavx): The First Non-Opioid Painkiller of a New Class in Decades
For the first time in decades a painkiller has arrived with a genuinely new mechanism: it switches off a sodium channel in peripheral nerves, and the pain signal never reaches the brain. Hence the promise — pain relief without addiction. Here is what the two phase 3 trials actually measured, why the comparison against an opioid ended differently than expected, what lies behind the «no risk of habituation» phrase, and why there is nothing yet to say about endometriosis.
September 10, 2026Ready to start your health journey?
Book a consultation and receive a personalized treatment plan designed specifically for you by me personally.